Head-to-head comparison of tirzepatide vs semaglutide for obesity treatment finds tirzepatide produces greater weight loss, establishing dual agonism superiority.
Key findingHead-to-head comparison of tirzepatide vs semaglutide for obesity treatment finds tirzepatide produc
What the researchers found
Head-to-head comparison of tirzepatide vs semaglutide for obesity treatment finds tirzepatide produces greater weight loss, establishing dual agonism superiority.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
1:1 randomization. Tirzepatide max tolerated: 10 or 15 mg. Semaglutide max tolerated: 1.7 or 2.4 mg. Both subcutaneous weekly.
How the study worked
In publication.
Who was studied
Adults with obesity without type 2 diabetes
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
The New England journal of medicine, 393(1), 26-36
Citation
Aronne, Louis J; Horn, Deborah Bade; le Roux, Carel W; Ho, Wayne; Falcon, Beverly L; Gomez Valderas, Elisa; Das, Sagar; Lee, Clare J; Glass, Leonard C; Senyucel, Cagri; Dunn, Julia P. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.. The New England journal of medicine, 393(1), 26-36. https://doi.org/10.1056/NEJMoa2416394